Volume 33, Issue 1 (April 2022)
Studies in Medical Sciences 2022, 33(1): 45-53 |
Back to browse issues page
Ethics code: SBU/1542/د
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Abidkanjo F, Soleimani N, Hosseini S M, Zanotti G. IMMUNOLOGICAL EFFECTS OF FLGE2 RECOMBINANT PROTEIN IN HELICOBACTER PYLORI ON TNF-A CYTOKINE PRODUCTION IN MACROPHAGE CELLS IN VITRO. Studies in Medical Sciences 2022; 33 (1) :45-53
URL: http://umj.umsu.ac.ir/article-1-5786-en.html
URL: http://umj.umsu.ac.ir/article-1-5786-en.html
Associate Professor of Medical Bacteriology, Department of Microbiology, School of Biotechnology, Shahid Beheshti School, Tehran, Iran (Corresponding Author) , n_soleimani@sbu.ac.ir
Abstract: (1756 Views)
Background & Aims: Helicobacter pylori is a gram-negative bacillus that can be colonized in the mucosal layers of the human stomach. According to the classification of the World Health Organization, this organism is among the class 1 carcinogens. Although numerous studies have been performed on the reaction between H. pylori and immune cells, however, the study of the reaction of individual pathogens with these cells can reveal obscure aspects of the pathogenesis of this bacterium. It is important to study the reaction between some pathogenic factors of H. pylori such as CagA and VacA with immune cells has begun. On the other hand, by examining the type of reaction of a factor that is considered also as a vaccine candidate, we can evaluate the type of immune cell stimulation behavior of the factor in vitro before injection of it into the laboratory animal. FlgE2 recombinant protein from H. pylori can be considered as a suitable candidate that has not been studied yet. The aim of this study was to evaluate the immunological effects of FlgE2 on the amount of TNF-alpha production in macrophage cells in laboratory conditions by ELISA method.
Materials & Methods: In this experimental study with the bioethical code of SBU/1542/D, FlgE2 recombinant protein was expressed and purified. Peritoneal macrophages of mice were extracted. Different concentrations of 4, 20, 40, and 80 μg/ml were used to evaluate the effects of recombinant protein on macrophage cells. Exposure supernatant was isolated and used to evaluate the effects of cytokines on ELISA.
Results: Based on statistical analysis, the highest secretion was observed at the concentration of 20 µg/ml and then at the concentration of 4 µg/ml (P<0.0001) and 40 µg/ml (P <0.0017). Statistical analysis shows that there was a significant and close difference at 4, 20, and 40 µg/ml, compared to the control group; however, the amount of TNF-α at the concentration of 80 µg/ml was not significantly different from control group (P = 0.4028).
Conclusion: This study showed that the recombinant FlgE2 protein is one of the important factors in the pathogenicity of H. pylori and its structure and function are very important for effective vaccine candidate strategies. This protein factor can stimulate the immune system and activate macrophages. As a result, investigation of the effects of this protein separately can lead to new treatment strategies and prevention of H. pylori infections, which has involved half of the world's population.
Materials & Methods: In this experimental study with the bioethical code of SBU/1542/D, FlgE2 recombinant protein was expressed and purified. Peritoneal macrophages of mice were extracted. Different concentrations of 4, 20, 40, and 80 μg/ml were used to evaluate the effects of recombinant protein on macrophage cells. Exposure supernatant was isolated and used to evaluate the effects of cytokines on ELISA.
Results: Based on statistical analysis, the highest secretion was observed at the concentration of 20 µg/ml and then at the concentration of 4 µg/ml (P<0.0001) and 40 µg/ml (P <0.0017). Statistical analysis shows that there was a significant and close difference at 4, 20, and 40 µg/ml, compared to the control group; however, the amount of TNF-α at the concentration of 80 µg/ml was not significantly different from control group (P = 0.4028).
Conclusion: This study showed that the recombinant FlgE2 protein is one of the important factors in the pathogenicity of H. pylori and its structure and function are very important for effective vaccine candidate strategies. This protein factor can stimulate the immune system and activate macrophages. As a result, investigation of the effects of this protein separately can lead to new treatment strategies and prevention of H. pylori infections, which has involved half of the world's population.
Type of Study: Research |
Subject:
میکروبیولوژی
References
1. Kranzer K, Söllner L, Aigner M, Lehn N, Deml L, Rehli M, Schneider-Brachert W. Impact of Helicobacter pylori virulence factors and compounds on activation and maturation of human dendritic cells. Infect Immun 2005;73(7):4180-9. [DOI:10.1128/IAI.73.7.4180-4189.2005] [PMID] [PMCID]
2. Sokolova O, Bozko PM, Naumann M. Helicobacter pylori Suppresses Glycogen Synthase Kinase 3β to Promote β-Catenin Activity. J Biol Chem 2008;283(43):29367-74. [DOI:10.1074/jbc.M801818200] [PMID] [PMCID]
3. Ahmadi Hedayati M, Khani D. Relationship of social risk factors and Helicobacter pylori infection with pathological characteristics of Gastric carcinoma. Iran J Med Microbiol 2020;14(1):43-30. [DOI:10.30699/ijmm.14.1.43]
4. 4 Kraft C, Stack A, Josenhans C, Niehus E, Dietrich G, Correa P, et al. Genomic changes during chronic Helicobacter pylori infection. J Bacteriol. 2006 Jan;188(1):249-54. [DOI:10.1128/JB.188.1.249-254.2006] [PMID] [PMCID]
5. Wen S, Velin D, Felley CP, Du L, Michetti P, Pan-Hammarström Q. Expression of Helicobacter pylori virulence factors and associated expression profiles of inflammatory genes in the human gastric mucosa. Infect Immun 2007;75(11):5118-26. [DOI:10.1128/IAI.00334-07] [PMID] [PMCID]
6. Honda S, Fujioka T, Tokieda M, Satoh R, Nishizono A, Nasu M. Development of Helicobacter pylori-induced gastric carcinoma in Mongolian Gerbils. Cancer Res 1998;58:4255-9. [Google Scholar]
7. Carlsohn E, Nyström J, Bölin I, Nilsson CL, Svennerholm AM. HpaA is essential for Helicobacter pylori colonization in mice. Infect Immun 2006;74(2):920-6. [DOI:10.1128/IAI.74.2.920-926.2006] [PMID] [PMCID]
8. Loconte V, Kekez I, Matković‐Čalogović D, Zanotti G. Structural characterization of FlgE2 protein from Helicobacter pylori hook. FEBS J 2017;284(24):4328-42. [DOI:10.1111/febs.14312] [PMID]
9. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketchum KA, Klenk HP, Gill S, Dougherty BA, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997;388(6642):539-47. [DOI:10.1038/41483] [PMID]
10. Yoon YH, Barker CS, Bulieris PV, Matsunami H & Samatey FA. Structural insights into bacterial flagellar hooks similarities and specificities. Sci Rep 2016;6(1):1-1. [DOI:10.1038/srep35552] [PMID] [PMCID]
11. O'Toole PW, Kostrzynska M, Trust TJ. Non‐motile mutants of Helicobacter pylori and Helicobacter mustelae defective in flagellar hook production. Mol Microb 1994;14(4):691-703. [DOI:10.1111/j.1365-2958.1994.tb01307.x] [PMID]
12. Tan ML, Choong PF, Dass CR. Review: doxorubicin delivery systems based on chitosan for cancer therapy. J Pharm Pharmacol 2009;61(2):131-42. [DOI:10.1211/jpp.61.02.0001] [PMID]
13. Saremi S, Atyabi F, Akhlaghi SP, Ostad SN, Dinarvand R. Thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: preparation, in vitro and ex vivo evaluation. Int J Nanomed 2011;6:119-28. [DOI:10.2147/IJN.S15500] [PMID] [PMCID]
14. Soleimani N, Mobarez A, Jafari Olia M, Atyabi F. Synthesis, Characterization and effect of the antibacterial activity of chitosan nanoparticles on vancomycin- resistant enterococcus and other gram negative or gram positive bacteriaint. J Pure Appl Sci Technol 2015;26(1):14-23. [Google Scholar]
15. Hosseinzadeh H, Atyabi F, Dinarvand R and Naser Ostad S. Chitosan-Pluronic nanoparticles as oral delivery of anticancer gemcitabine: Preparation and in vitro study. Int J Nanomed 2012;7:1851-63. [DOI:10.2147/IJN.S26365] [PMID] [PMCID]
16. Soleimani N, Mohabati-Mobarez A, Atyabi F, Hasan-Saraf Z, Haghighi M. Preparation of chitosan nanoparticles carrying recombinant helicobacter pylori neutrophil-activating protein. J Mazandaran Univ Med Sci 2014;23(2):134-44. [Google Scholar]
17. Daneshmandi S, Hajimoradi M, Soleimani N, Sattari M. Modulatory effect of Acetobacter xylinum cellulose on peritoneal macrophages. Immunopharmacol Immunotoxicol 2011;33(1):164-8. [DOI:10.3109/08923973.2010.491080] [PMID]
18. Yousofi A, Daneshmandi S, Soleimani N, Bagheri K, Karimi MH. Immunomodulatory effect of Parsley (Petroselinum crispum) essential oil on immune cells: mitogen-activated splenocytes and peritoneal macrophages. Immunopharmacol Immunotoxicol 2012;34(2):303-8. [DOI:10.3109/08923973.2011.603338] [PMID]
19. Soleimani N, Mohabati-Mobarez A, Atyabi F, Hasan-Saraf Z, Al Haghighi M. Preparation of chitosan nanoparticles carrying recombinant Helicobacter pylori neutrophilactivating protein. J Mazandaran Univ Med Sci 2014:23:134-44. [Google Scholar]
20. Soleimani, N., & Mobarez, A. M. Effect of recombinant neutrophil-activating protein (HP-NAP) of Helicobacter pylori on peritoneal macrophages. Iran J Pub Health 2014:43(2), 234. [Google Scholar]
21. Hedayati MA, Salavati S. Transcriptional Profile of Helicobacter pylori Virulence Genes in Patients with Gastritis and Gastric Cancer. Can J Infect Dis Med Microbiol 2021;10:1309519. [DOI:10.1155/2021/1309519] [PMID] [PMCID]
22. Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterol 1998:115(3):642-8. [DOI:10.1016/S0016-5085(98)70143-X] [PMID]
23. Antani JD, Sumali AX, Lele TP, Lele PP. Asymmetric random walks reveal that the chemotaxis network modulates flagellar rotational bias in Helicobacter pylori. Elife 2021;10:e63936. [DOI:10.7554/eLife.63936] [PMID] [PMCID]
24. Gu H. Role of Flagella in the Pathogenesis of Helicobacter pylori.Curr Microb2017;74(7):863-9. [DOI:10.1007/s00284-017-1256-4] [PMID] [PMCID]
25. Zarei M, Mosayebi G, Khansarinejad B, Abtahi H. Antigenic and immunogenic evaluation of Helicobacter pylori FlaA epitopes. Iran J Basic Med Sci 2017;20(8):920. [PMCID]
26. Kusters JG, Van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clinical Microb Rev 2006;19(3):449-90. [DOI:10.1128/CMR.00054-05] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
